COVID-19

As a research-driven company, we are part of the collective effort in fighting COVID-19. Boehringer Ingelheim does not develop human vaccines; however, drawing from our different areas of expertise we have engaged in a number of activities to find medical solutions to this pandemic, working closely with academic researchers, international institutions and others in the pharma industry.

Fighting COVID-19

We conducted computational screening of our entire molecule library of more than one million compounds. Existing compounds from our current pipeline and portfolio were also tested as potential treatments for patients. We are involved in the research and development of SARS-CoV-2 antibodies that can neutralize the virus and the development of therapies to prevent blood clots. ​

Learn more about our ongoing engagement in the fight against COVID-19.​​

Q&A for Patients

Here you can find general information, as well as questions and answers for patients living with certain diseases, like chronic respiratory conditions or diabetes.

COVID-19: Research Update
COVID-19: Phase 2 Clinical Trial
COVID-19

COVID-19: Research Update

Boehringer Ingelheim stops treatment with experimental medication in study investigating benefits for severely ill patients with COVID-19
protecting humans and animals

Protecting animals and humans

Everything we do is about improving the health and well-being of humans and animals. During these trying times, all of us at Boehringer Ingelheim are committed to ensuring the continued availability of our products for patients, customers and animals. We are here to support patients, their families and healthcare professionals with the tools, resources and information they need.

Related Press Releases